Company Description
DHC is a real estate investment trust, or REIT, focused on owning high-quality healthcare properties located throughout the United States.
DHC seeks diversification across the health services spectrum by care delivery and practice type, by scientific research disciplines and by property type and location.
As of December 31, 2023, DHC's approximately $7.2 billion portfolio included 371 properties in 36 states and Washington, D.C., occupied by approximately 500 tenants, and totaling approximately 8.6 million square feet of life science and medical office properties and more than 27,000 senior living units.
DHC is managed by The RMR Group (Nasdaq: RMR), a leading U.S. alternative asset management company with over $41 billion in assets under management as of December 31, 2023 and more than 35 years of institutional experience in buying, selling, financing and operating commercial real estate.
DHC is headquartered in Newton, MA.
| Country | United States |
| Industry | REIT - Healthcare Facilities |
| Sector | Real Estate |
| Employees | 600 |
| CEO | Christopher J. Bilotto |
Contact Details
Address: C/o The Rmr Group, Two Newton Pl., 255 Wash. St., Ste. 300 Newton, Massachusetts 02458 United States | |
| Phone | (617) 796-8350 |
| Website | dhcreit.com |
Stock Details
| Ticker Symbol | DHC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001075415 |
| CUSIP Number | 25525P107 |
| ISIN Number | US25525P1075 |
| Employer ID | 04-3445278 |
| SIC Code | 6798 |
Key Executives
| Name | Position |
|---|---|
| Christopher J. Bilotto | President and Chief Executive Officer |
| Adam David Portnoy | Managing Chair of the Board |
| Matthew C. Brown | Chief Financial Officer and Treasurer |
| Michael B. Kodesch | Director of Investor Relations |
| David M. Blackman | Director of Acquisition |
| Jennifer Babbin Clark | Secretary |
| Melissa Mccarthy | Manager of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 28, 2024 | EFFECT | Notice of Effectiveness |
| Jun 21, 2024 | DEL AM | Filing |
| Jun 20, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 4, 2024 | 8-K | Current Report |
| Jun 3, 2024 | 8-K | Current Report |
| May 21, 2024 | 8-K | Current Report |
| May 6, 2024 | 10-Q | Quarterly Report |
| May 6, 2024 | 8-K | Current Report |
| Mar 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 26, 2024 | DEF 14A | Other definitive proxy statements |